Efficacy versus toxicity - The ying and yang in translating nanomedicines

Nanomaterials and Nanotechnology

Volumn 4, Issue 1, 2014, Pages

  Shankarappa, Sahadev A ^a   Koyakutty, Manzoor ^a   Nair, Shantikumar V ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Efficacy; Nanomedicine; Nanotechnology; Toxicity; Translational medicine

Indexed keywords

ENZYME INHIBITION; NANOTECHNOLOGY; TOXICITY;

ASSESSMENT TOOL; BIOMEDICAL RESEARCH; EFFICACY; NOVEL STRATEGIES; OVERALL BENEFIT; PRECLINICAL STUDIES; TRANSLATIONAL FAILURE; TRANSLATIONAL MEDICINE;

MEDICAL NANOTECHNOLOGY;

EID: 84908254448     PISSN: None     EISSN: 18479804     Source Type: Journal    
DOI: 10.5772/59127     Document Type: Article

References (28)

1. National Nanotechnology Initiative. (2013) Supplement to the President's FY 2014 Budget. Washington, DC, National Science and Technology Council.
2. Roco MC, Chad MA and Mark HC (2010) Nanotechnology Research Directions for Societal Needs in 2020 Retrospective and Outlook. WTEC Panel Report 1-607.
3. Shankarappa SA and Kohane DS (2013) Controlledrelease systems in neuropathic pain. Pain Management, Future Medicine 3: 91-3. http://dx.doi.org/10.2217/pmt.12.82.
4. Shankarappa SA, Tsui JH, Kim KN, Reznor G, Dohlman JC, Langer R et al. (2012) Prolonged nerve blockade delays the onset of neuropathic pain. Proceedings of the National Academy of Sciences 109: 17555-60. http://dx.doi.org/10.1073/pnas.1214634109/-/DCSupplemental/pnas.201214634SI.pdf.
5. Weldon CB, Tsui JH, Shankarappa SA, Nguyen VT, Ma M, Anderson DG et al. (2012) Electrospun drugeluting sutures for local anesthesia. Journal of Controlled Release: Official Journal of the Controlled Release Society 161: 903-9. http://dx.doi.org/10.1016/j.jconrel.202.05.021.
6. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V and Langer R (1994) Biodegradable longcirculating polymeric nanospheres. Science (New York, NY) 263: 1600-3.
7. Newman MS, Colbern GT, Working PK, Engbers C and Amantea MA (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemotherapy and Pharmacology 43: 1-7. http://dx.doi.org/10.1007/s002800050855.
8. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG et al. (2001) Phase III study of pegylated liposomal cisplatin (SPI-077 TM) in patients with inoperable head and neck cancer. Annals of Oncology, Eur Soc Med Oncology 12: 493-6.
9. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z et al. (1998) Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicological Sciences: an Official Journal of the Society of Toxicology 46: 155-65. http://dx.doi.org/10.1006/toxs.1998.2555.
10. Igarashi E (2008) Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicology and Applied Pharmacology 229: 121-34. http://dx.doi.org/10.1016/j.taap.2008.02.007.
11. Padera R, Bellas E, Tse JY, Hao D and Kohane DS (2008) Local myotoxicity from sustained release of bupivacaine from microparticles. Anesthesiology 108: 921-8. http://dx.doi.org/10.1097/ALN.0b013e31816c8a48.
12. Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R et al. (2012) Best practices in cancer nanotechnology: perspective from NCI Nanotechnology Alliance. Clinical Cancer Research 18: 3229-41. http://dx.doi.org/10.1158/1078-0432.CCR-11-2938.
13. Adiseshaiah PP, Hall JB and McNeil SE (2010) Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Wiley Online Library 2: 99-112. http://dx.doi.org/10.1002/wnan.066.
14. Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C et al. (2009) Nanoparticle dermal absorption and toxicity: a review of the literature. International Archives of Occupational and Environmental Health 82: 1043-55. http://dx.doi.org/10.1007/s00420-009-0458-x.
15. Li JJ, Muralikrishnan S, Ng CT, Yung LYL and Bay BH (2010) Nanoparticle-induced pulmonary toxicity. Experimental Biology and Medicine (Maywood, NJ) 235: 1025-33. http://dx.doi.org/10.1258/ebm.2010.010021.
16. Yang Z, Liu ZW, Allaker RP, Reip P, Oxford J, Ahmad Z et al. (2010) A review of nanoparticle functionality and toxicity on the central nervous system. Journal of the Royal Society, Interface/the Royal Society, 7 Suppl 4: S411-22. http://dx.doi.org/10.1098/rsif.2010.0158.focus.
17. Duncan R and Gaspar R (2011) Nanomedicine(s) under the microscope. Molecular Pharmaceutics 8: 2101-41. http://dx.doi.org/10.1021/mp200394t.
18. Manikandan M, Hasan N and Wu HF (2013) Platinum nanoparticles for the photothermal treatment of Neuro 2A cancer cells. Biomaterials 34: 5833-42. http://dx.doi.org/10.1016/j.biomaterials.2013.03.077.
19. Liu X, Wei W, Wang C, Yue H, Ma D, Zhu C et al. (2011) Apoferritin-camouflaged Pt nanoparticles: surface effects on cellular uptake and cytotoxicity. Journal of Materials Chemistry 21: 7105. http://dx.doi.org/10.1039/c1jm10575b.
20. Ludwig T, Riethmuller C, Gekle M, Schwerdt G and Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney International, Nature Publishing Group 66: 196-202. http://dx.doi.org/10.1111/j.1523-1755.2004.00720.x.
21. Madias NE and Harrington JT (1978) Platinum nephrotoxicity. The American Journal of Medicine 65: 307-14. http://dx.doi.org/10.1016/0002-9343(78)90825-2.
22. Rathore AS (2009) Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends in Biotechnology 27: 546-53. http://dx. doi. org/10. 1016/j. tibtech. 2009. 06. 006.
23. Flynn T and Wei C (2005) The pathway to commercialization for nanomedicine. Nanomedicine: Nanotechnology, Biology, and Medicine 1: 47-51. http://dx.doi.org/10.1016/j.nano. 2004.11.010.
24. Murday JS, Siegel RW, Stein J and Wright JF (2009) Translational nanomedicine: status assessment and opportunities. Nanomedicine: Nanotechnology, Biology, and Medicine, Elsevier Inc 5: 251-73. http://dx.doi.org/10.1016/j.nano.2009.06.001.
25. Mankoff SP, Brander C, Ferrone S and Marincola FM (2004) Lost in translation: obstacles to translational medicine. Journal of Translational Medicine, BioMed Central Ltd 2, 14. http://dx.doi.org/10.1186/1479-5876-2-14.
26. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V et al. (2010) Can animal models of disease reliably inform human studies? PLoS Medicine 7, e1000245. http://dx.doi.org/10.1371/journal.pmed.1000245.
27. Chandran P, Gupta N, Retnakumari AP, Malarvizhi GL, Keechilat P, Nair S et al. (2013) Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. Nanomedicine: Nanotechnology, Biology, and Medicine. http://dx. doi. org/10. 1016/j. nano. 2013. 04. 012.
28. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH et al. (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. Journal of Controlled Release 127: 41-9. http://dx.doi.org/10.1016/j.jconrel.2007.12.014.